Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

SinoFresh debut

This article was originally published in The Tan Sheet

Executive Summary

"Moisturizing Nasal & Sinus Spray" is reaching nationwide distribution at Walgreens stores and also will be available at Publix supermarkets in the southeast, SinoFresh Healthcare announces July 10. SinoFresh Nasal & Oral Care, which claims to "kill nasal mold and bacteria" and "clear nasal passages," contains .05% cetylpyridinium chloride in a "clinically proven, non addictive" formula. Spray will be available in the cough/cold section of stores; a 1 oz. bottle costs under $20 and contains roughly a one-month supply with twice-daily usage, firm says. SinoFresh Research Labs recently petitioned FDA to include the nasal spray in the TFM for Oral Antiseptic Drugs (1"The Tan Sheet" April 7, 2003, p. 7)...

You may also be interested in...



Cetylpyridinium Nasal Spray Status As Category I Oral Antiseptic Requested

Inclusion of a nasal spray containing .05% cetylpyridinium chloride in FDA's tentative final monograph for Oral Antiseptic Drug Products is requested by SinoFresh Research Labs in a March 24 citizen petition

Prenatal Vitamin D Benefit In Preventing Childhood Asthma Fades By Age 6

University of Rochester researchers say a benefit of daily prenatal vitamin D in preventing asthma in children up to 3 found in their 2016 study doesn't extend until age 6. They encourage more research, including analyzing whether supplementation should continue in young children.

UK Reveals Plans For ‘Dynamic’ Post-Brexit Regulatory System

At the end of the Brexit transition period, the UK will be charting its own course through the often choppy seas of medicines regulation. While it plans to retain the existing EU rules that have been transposed into domestic legislation, it also wants the freedom to tailor its regulations in areas like clinical trials, advanced therapies and product labeling.

Topics

UsernamePublicRestriction

Register

PS095694

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel